Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIMAL Trial
NCT07058155Phase 4Recruiting
- Sponsor
- Cleveland Clinic
- Start
- Dec 2025
- Primary completion
- Feb 2029
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in Cirrhosis, obesity and Portal Hypertension (PH) (2 arms), sponsored by Cleveland Clinic. Primary endpoint: Change in SF-36 Physical Component Summary Score at 6 months. Started Dec 2025; status: recruiting.
02
Conditions
CirrhosisobesityPortal Hypertension (PH)
Beyond the preview
Go deeper on NCT07058155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07058155.